Bandingkan Harga & Kinerja Cipta Sarana Medika Tbk. (DKHH) vs Malindo Feedmill Tbk. (MAIN)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Cipta Sarana Medika Tbk. dan Malindo Feedmill Tbk.: Cipta Sarana Medika Tbk. diperdagangkan di Rp63 (kapitalisasi pasar 160,67 M, volume 24 jam 10,67 jt), sedangkan Malindo Feedmill Tbk. diperdagangkan di Rp680 (kapitalisasi pasar 1,51 T, volume 24 jam 399,5 rb). Perbedaan utamanya: Malindo Feedmill Tbk. jauh lebih besar — sekitar 9,4× kapitalisasi pasar Cipta Sarana Medika Tbk., dan Cipta Sarana Medika Tbk. lebih aktif diperdagangkan (10,67 jt vs 399,5 rb). Mana yang lebih baik tergantung tujuan investasimu.
| DKHH | MAIN | |
|---|---|---|
Kapitalisasi Pasar | 160,67 M | 1,51 T |
Volume | 10,67 jt | 399,5 rb |
Lot | 106,74 rb | 4 rb |
Perputaran | 663,84 jt | 270,4 jt |
Harga Rata-rata | 62,19 | 676,84 |
Nilai Transaksi | 663,84 jt | 270,4 jt |
Harga Ekuilibrium Indikatif | 63 | 680 |
Volume Ekuilibrium Indikatif | 500 | 17 |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Cipta Sarana Medika Tbk.
PT Cipta Sarana Medika Tbk (the Company) was established based on Deed No. 90 dated September 17, 2014 by Dede Fujianti, SH., M.Kn., Notary in Sukabumi. The Company ultimate parent entity is PT Siliwangi Djajakusumah Bersatu. The Company started its commercial operations in 2014.
Selengkapnya di halaman DKHH →Tentang Malindo Feedmill Tbk.
PT Malindo Feedmill Tbk (the Company) was established within the framework of Law No. 1 of 1967 and Law No. 11 of 1970 regarding Foreign Capital Investment. The Company was established under its original name PT Gymtech Feedmill on June 10, 1997. The company's name changed to PT Malindo Feedmill in year 2000. The company’s articles of association were amended several times, the lates on Jul 28 2005, regarding among other increasing in paid up capital share.
Selengkapnya di halaman MAIN →
